My watch list
my.bionity.com  
Login  

Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth

GBI Research’s report, “Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles and to Create Opportunities for Growth”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market. The report analyzes the markets for kidney and renal diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

Report Highlights
GBI Research, the leading business intelligence provider, has released its latest research, “Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth”, which provides insights into the global kidney and renal diseases therapeutics market and market forecasts until 2017. The report provides an in-depth analysis of the top four therapeutic indications of kidney and renal diseases, which includes chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury. The report also examines the global kidney and renal disease treatment usage patterns for the covered indications. In addition, the report also includes insights into the kidney and renal diseases R&D pipeline. GBI Research analysis shows that the overall global kidney and renal diseases market for the four indications, chronic kidney disease, renal anemia, diabetic nephropathy and acute kidney injury was valued at $50.3 billion in 2010. The market is expected to witness growth at a CAGR of 5.5% for the forecast period, and will reach $73 billion by 2017. The global market revenues are expected to increase due to the introduction of new therapies which are currently in the regulatory filing stage, and those in the later stages of development. These drugs include antioxidant inflammatory modulators, metal-free phosphate binders with improved safety and efficacy, nutritional supplements and iron replacement therapies.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Kidney and Renal Diseases Therapeutics Market is Forecast to Show Moderate Growth Until 2017

GBI Research’s analysis suggests that the global kidney and renal diseases therapeutics market was worth $50.3 billion in 2010. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.5% for the next seven years, to reach $73 billion by 2017. The global market revenues are expected to increase due to the introduction of new therapies which are currently in the regulatory filing stage, and those in the later stages of development. These drugs include antioxidant inflammatory modulators, metal-free phosphate binders with improved safety and efficacy, nutritional supplements and iron replacement therapies.

Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017

Source: GBI Research, Centers for Disease Control and Prevention (CDC)

Competition among Marketed Products is Weak

GBI Research analyzed the current competitive landscape for kidney and renal disease drugs and found the competition to be weak. There are more than 12 marketed products for the treatment of CKD, including angiotensin II receptor blockers (ARB), Angiotensin Converting Enzyme (ACE) inhibitors, phosphate binders, Erythropoietin (EPO) and iron replacement products. Although these products are moderately effective in controlling the progression of CKD, the serious adverse effects of these products have resulted in the discontinuation of therapies amongst patients. The market is in need of a first-in-class product which is efficient in slowing down the progression of CKD.

Poor Safety Profiles of Existing Therapies Create Unmet Needs That Attract Investment in the Pipeline

GBI Research has found that the global kidney and renal disease therapeutics market is highly lucrative, as there is a substantial amount of unmet need to be satisfied with respect to the safety of medications. Serious adverse events associated with lanthanum carbonate, sevelamer carbonate, sevelamer hydrochloride and other phosphate binders create a need for products with better safety profiles and higher efficacy. In addition, the dosing regimen of the products is highly prohibitive for patients to remain on long-term treatment. As a result of discontinuation, only half of the patients meet the hyperphosphatemia treatment guidelines required for slowing down the disease progression.

The kidney and renal diseases therapeutics market product pipeline consists of 165 new molecules in the various stages of clinical trials, as indicated below:

Kidney and Renal Diseases Therapeutics Market, Global Product Pipeline by Phase (%), 2011

Source: GBI Research, Company Websites

Pharmacy / Drugs   Market study
Year:   2011
Publisher:   GBI Research
Price:   3,500.00€
More about GBI Research
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE